Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00297232




Registration number
NCT00297232
Ethics application status
Date submitted
27/02/2006
Date registered
28/02/2006
Date last updated
15/07/2016

Titles & IDs
Public title
Natalizumab (Tysabri) Re-Initiation of Dosing
Scientific title
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation
Secondary ID [1] 0 0
101-MS-321
Universal Trial Number (UTN)
Trial acronym
STRATA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing-Remitting Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Natalizumab

Experimental: Natalizumab - 300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks


Treatment: Drugs: Natalizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to 24-week Confirmed Expanded Disability Status Scale (EDSS) Progression
Timepoint [1] 0 0
up to 480 weeks
Primary outcome [2] 0 0
Time to 48-week Confirmed EDSS Progression
Timepoint [2] 0 0
up to 480 weeks
Primary outcome [3] 0 0
Time to 24-week Confirmed EDSS Improvement Where Baseline = 2.0
Timepoint [3] 0 0
Up to 480 weeks

Eligibility
Key inclusion criteria
Key Inclusion Criteria

- MS subjects who completed Study C-1801 (NCT00027300), C-1802 (NCT00030966), or C-1803
(NCT00097760) and a Dosing Suspension Safety Evaluation (neurological examination or a
magnetic resonance imaging scan) or participated in the IMA 04001 (STARS) Study

- Subjects who are considered by the Investigator to be free of signs and symptoms
suggestive of progressive multifocal leukoencephalopathy and willing to discontinue
and remain free from concomitant immunosuppressive or immunomodulatory treatment
(including IFN-beta and glatiramer acetate) while being treated with natalizumab
during the study.

- In addition, subjects who completed 48 weeks of treatment in Study 101-MS-322
(NCT00306592) in Canada will be allowed to enter this study at the start of the
long-term treatment period (Week 52 - 480).

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Considered by the Investigator to be immunocompromised

- History of persistent anti-natalizumab antibodies, based upon testing from prior
natalizumab studies

- History of any major disease or malignancy

- Discontinued natalizumab in a previous study due to allergic reaction

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/03/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2014
Sample size
Target
Accrual to date
Final
1094
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Heidelberg
Recruitment hospital [3] 0 0
Research Site - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3084 - Heidelberg
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Brugge
Country [2] 0 0
Belgium
State/province [2] 0 0
Brussels
Country [3] 0 0
Belgium
State/province [3] 0 0
Charleroi
Country [4] 0 0
Belgium
State/province [4] 0 0
Diepenbeek
Country [5] 0 0
Belgium
State/province [5] 0 0
Melsbroek
Country [6] 0 0
Belgium
State/province [6] 0 0
Sijsele
Country [7] 0 0
Canada
State/province [7] 0 0
British Columbia
Country [8] 0 0
Canada
State/province [8] 0 0
Nova Scotia
Country [9] 0 0
Canada
State/province [9] 0 0
Ontario
Country [10] 0 0
Canada
State/province [10] 0 0
Quebec
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Brno
Country [12] 0 0
Czech Republic
State/province [12] 0 0
Hradec Kralove
Country [13] 0 0
Czech Republic
State/province [13] 0 0
Olomouc
Country [14] 0 0
Czech Republic
State/province [14] 0 0
Ostrava
Country [15] 0 0
Czech Republic
State/province [15] 0 0
Pardubice
Country [16] 0 0
Czech Republic
State/province [16] 0 0
Plzen
Country [17] 0 0
Czech Republic
State/province [17] 0 0
Praha 2
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Praha 5
Country [19] 0 0
Denmark
State/province [19] 0 0
Aarhus C
Country [20] 0 0
Denmark
State/province [20] 0 0
Esbjerg
Country [21] 0 0
Denmark
State/province [21] 0 0
Kobenhavn
Country [22] 0 0
Finland
State/province [22] 0 0
Helsinki
Country [23] 0 0
Finland
State/province [23] 0 0
Tampere
Country [24] 0 0
Finland
State/province [24] 0 0
Turku
Country [25] 0 0
France
State/province [25] 0 0
Besancon
Country [26] 0 0
France
State/province [26] 0 0
Bordeaux
Country [27] 0 0
France
State/province [27] 0 0
Clermont-Ferrand
Country [28] 0 0
France
State/province [28] 0 0
Creteil
Country [29] 0 0
France
State/province [29] 0 0
Dijon
Country [30] 0 0
France
State/province [30] 0 0
Lille
Country [31] 0 0
France
State/province [31] 0 0
Lyon
Country [32] 0 0
France
State/province [32] 0 0
Marseille
Country [33] 0 0
France
State/province [33] 0 0
Nancy
Country [34] 0 0
France
State/province [34] 0 0
Paris
Country [35] 0 0
France
State/province [35] 0 0
Rennes
Country [36] 0 0
France
State/province [36] 0 0
Strasbourg
Country [37] 0 0
France
State/province [37] 0 0
Toulouse
Country [38] 0 0
Germany
State/province [38] 0 0
Berlin
Country [39] 0 0
Germany
State/province [39] 0 0
Essen
Country [40] 0 0
Germany
State/province [40] 0 0
Gießen
Country [41] 0 0
Germany
State/province [41] 0 0
Hannover
Country [42] 0 0
Germany
State/province [42] 0 0
Hennigsdorf
Country [43] 0 0
Germany
State/province [43] 0 0
München
Country [44] 0 0
Germany
State/province [44] 0 0
Offenbach
Country [45] 0 0
Germany
State/province [45] 0 0
Osnabrück
Country [46] 0 0
Germany
State/province [46] 0 0
Regensburg
Country [47] 0 0
Germany
State/province [47] 0 0
Rostock
Country [48] 0 0
Greece
State/province [48] 0 0
Athens
Country [49] 0 0
Hungary
State/province [49] 0 0
Budapest
Country [50] 0 0
Hungary
State/province [50] 0 0
Debrecen
Country [51] 0 0
Hungary
State/province [51] 0 0
Gyor
Country [52] 0 0
Hungary
State/province [52] 0 0
Nyiregyhaza
Country [53] 0 0
Hungary
State/province [53] 0 0
Szekesfehervar
Country [54] 0 0
Ireland
State/province [54] 0 0
Dublin
Country [55] 0 0
Israel
State/province [55] 0 0
Jerusalem
Country [56] 0 0
Israel
State/province [56] 0 0
Tel Hashomer
Country [57] 0 0
Italy
State/province [57] 0 0
Bari
Country [58] 0 0
Italy
State/province [58] 0 0
Genova
Country [59] 0 0
Italy
State/province [59] 0 0
Milano
Country [60] 0 0
Italy
State/province [60] 0 0
Roma
Country [61] 0 0
Netherlands
State/province [61] 0 0
Amsterdam
Country [62] 0 0
Netherlands
State/province [62] 0 0
Breda
Country [63] 0 0
Netherlands
State/province [63] 0 0
Hertogenbosch
Country [64] 0 0
Netherlands
State/province [64] 0 0
Nieuwegein
Country [65] 0 0
Netherlands
State/province [65] 0 0
Nijmegen
Country [66] 0 0
Netherlands
State/province [66] 0 0
Rotterdam
Country [67] 0 0
New Zealand
State/province [67] 0 0
Auckland
Country [68] 0 0
New Zealand
State/province [68] 0 0
Christchurch
Country [69] 0 0
Poland
State/province [69] 0 0
Bialystok
Country [70] 0 0
Poland
State/province [70] 0 0
Bydgoszcz
Country [71] 0 0
Poland
State/province [71] 0 0
Gdansk
Country [72] 0 0
Poland
State/province [72] 0 0
Katowice
Country [73] 0 0
Poland
State/province [73] 0 0
Kraków
Country [74] 0 0
Poland
State/province [74] 0 0
Lodz
Country [75] 0 0
Poland
State/province [75] 0 0
Lublin
Country [76] 0 0
Poland
State/province [76] 0 0
Warsaw
Country [77] 0 0
Poland
State/province [77] 0 0
Warszawa
Country [78] 0 0
Spain
State/province [78] 0 0
Barcelona
Country [79] 0 0
Spain
State/province [79] 0 0
Málaga
Country [80] 0 0
Sweden
State/province [80] 0 0
Goteborg
Country [81] 0 0
Sweden
State/province [81] 0 0
Stockholm
Country [82] 0 0
Switzerland
State/province [82] 0 0
Basel
Country [83] 0 0
Turkey
State/province [83] 0 0
Ankara
Country [84] 0 0
Turkey
State/province [84] 0 0
Istanbul
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Essex
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Liverpool
Country [87] 0 0
United Kingdom
State/province [87] 0 0
London
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Newcastle Upon Tyne
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Oxford
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Sheffield
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Stoke on Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Biogen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objectives for the initial treatment period of this study are to further evaluate
the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions
and immunogenicity following re-exposure to natalizumab and confirming the safety of
switching from interferon (IFN), glatiramer acetate, or other multiple sclerosis (MS)
therapies to natalizumab. The primary objective for the long-term treatment period of this
study is to evaluate the long-term impact of natalizumab monotherapy on the progression of
disability measured by Expanded Disability Status Scale (EDSS) changes over time.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00297232
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Biogen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00297232